China bans corrupt drug makers
Vietnam bans drugs from India
Sun Pharma settles Gleevac issue
USFDA bans Wockhardt US plant
Ranbaxy recalls generic drugs
China takes stringent action against pharma companies involved in bribing doctors and other health authorities by barring them for selling products in the country.
China's National Health and Family Planning Commission introduced new regulations aimed at hospitals and physicians, as well as the medical product companies to sign Integrity Agreements by detailing names of their sales representatives and avoiding any deal with pharma company that takes corrupt route of business.
Questioning the quality standards of drugs exported by India drug makers, Drug Administration of Vietnam banned around 45 Indian pharmaceutical companies. Some of them including Strides Arcolab, Medley Pharmaceuticals, Marck Biosciences, Marksans Pharma and UMedica Laboratories. India is one of the largest suppliers of medicines to South-East Asian countries including Vietnam and African countries like Kenya, Nigeria and Ghana.
Facing a stiff threat from India's Sun Pharmaceuticals for gaining tentative USFDA approval for the Novartis' patent expiring blockbuster drug Gleevec, the drug developer settled with generics maker for a seven-month reprieve from the competition.
Indicated for leukemia, generic of Gleevec is a major loss for Novartis. Post settlement, Sun is allowed to launch a generic version of Gleevec in the United States only in 2016, that gives Novartis seven months to generate profit.
FDA lashed out at India's pharma company Wockhardt for using unsafe drug-testing procedures at it US plant.
Raising red flag at Wockhardt quality standards hit the company's first quarter revenue of 2014 by 94 percent.
FDA slammed Wockhardt for unsanitary conditions and poor employee sanitation at its plant and uncontrolled use of trial injections during chromatographic testing to release drug products.
India based Ranbaxy, that has been under quality compliance scan of FDA, recalled more than 64,000 bottles a generic of Lipitor, indicated to lower cholesterol, in the US, for containing tablets of atorvastatin calcium.
FDA declared the recall of Lipitor generic by Ranbaxy as Class II, which signifies a remote chance of severe adverse consequences or death due to the product flaw.